ArticleJournal of ovarian research2026
Serum long noncoding RNA FAM83H-AS1 serves as a potential noninvasive diagnostic biomarker for ovarian cancer.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe long noncoding RNA (lncRNA) FAM83H-AS1 plays a critical role in the development and progression of various cancers. This study evaluates the feasibility of serum FAM83H-AS1 as a diagnostic and staging marker for ovarian cancer (OC), addressing its previously unclear diagnostic value.
methodsOur study included 118 patients diagnosed with OC, 73 individuals with benign ovarian disease (BOD), and 61 healthy controls (HCs). The expression of serum FAM83H-AS1 was quantified via RNA extraction followed by RT-qPCR. The levels of CA125 and HE4 were detected via a chemiluminescence microparticle immunoassay, and the risk of ovarian malignancy algorithm (ROMA) was calculated. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic effect of FAM83H-AS1. Univariate and multivariate Cox regression analyses were employed to identify independent prognostic factors, while Kaplan–Meier analysis with the log-rank test was used to compare survival differences.
resultsThe levels of FAM83H-AS1 were significantly elevated in OC patients compared with those in individuals with BOD and HCs (P < 0.001). Additionally, FAM83H-AS1 expression levels were markedly higher in advanced TNM stages and in cases of metastasis. ROC curve analysis demonstrated robust diagnostic performance for FAM83H-AS1 alone (AUC = 0.824), and the combined FAM83H-AS1 + ROMA panel achieved superior accuracy (AUC = 0.909). Stepwise multivariate analysis identified FAM83H-AS1 as an independent diagnostic predictor for OC. A unit increase in this marker was associated with a 6.9% increase in the odds of OC (P = 0.030). FAM83H-AS1 levels were positively correlated with TNM stage, lymphatic metastasis, distal metastasis, peritoneal metastasis, and established biomarkers (CA125, HE4, and ROMA; P < 0.05). Notably, postoperative FAM83H-AS1 levels were significantly lower in 22 paired patients (P < 0.01), confirming its tumor-derived origin. Survival analysis indicated that elevated serum levels of FAM83H-AS1 expression serve as an independent prognostic factor associated with decreased progression-free survival (PFS) (HR = 8.251, P = 0.041). However, it failed to exhibit independent prognostic significance for overall survival (OS), as the correlation with OS observed in the univariate analysis was rendered non-significant in the multivariate analysis after adjusting for TNM stage. Kaplan-Meier curves further validated significantly worse survival outcomes for patients categorized in the high-expression group (P < 0.05).
conclusionsThis research is the first to indicate that serum FAM83H-AS1 may serve as a novel noninvasive biomarker for the diagnosis of OC. The combination of FAM83H-AS1 and ROMA demonstrated excellent diagnostic efficacy. Serum FAM83H-AS1 is promising for monitoring the stage and progression of OC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.